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Background. Antimalarial use is a key factor driving drug resistance and reduced treatment effectiveness in
Plasmodium falciparum malaria, but there are few formal, quantitative analyses of this process.
Methods. We analyzed drug usage, drug failure rates, and the frequencies of mutations and haplotypes known
to be associated with drug resistance over a 12-year period (1991–2002) in a site in Papua New Guinea. This
period included 2 successive treatment policies: amodiaquine (AQ) or chloroquine (CQ) from 1991 through 2000
and their subsequent replacement by sulfadoxine-pyrimethamine (SP) plus AQ or SP plus CQ.
Results. Drug use approximated 1 treatment per person-year and was associated with increasing frequencies
of pfcrt and pfmdr1 mutations and of treatment failure. The frequency of pfdhfr mutations also increased, especially
after the change in treatment policy. Treatment failure rates multiplied by 3.5 between 1996 and 2000 but then
decreased dramatically after treatment policy change.
Conclusions. With high levels of resistance to CQ, AQ, and SP, the deployment of the combination of both
drugs appears to increase clinical effectiveness but does not decelerate growth of resistance. Our estimates of
mutation and haplotype frequencies provide estimates of selection coefficients acting in this environment, which
are key parameters for understanding the dynamics of resistance.
Mass deployment of antimalarial drugs invariably re-
sults in emergence and spread of resistance. The effec-
tiveness of the most widely used antimalarials, chlo-
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roquine (CQ) and sulfadoxine-pyrimethamine (SP),
was heavily compromised by the emergence and spread
of resistant Plasmodium falciparum [1]. The genetic ba-
sis of this resistance is known in some detail: resistance
to CQ and SP is associated with accumulation of mu-
tations in pfcrt/pfmdr1 and pfdhfr/pfdhps genes, respec-
tively [2–4], which have spread within and across con-
tinents [5–7]. Here, we use a unique 12-year compilation
of clinical records of drug use, molecular analyses of
blood samples, and longitudinal morbidity surveillance
to quantify the 3 key components of the process leading
to drug failure:
1. The driving force for resistance: the level of com-
munity drug use.
2. The mediator: the spread of resistance-associated
mutations.
3. The outcome: drug failure and reduced effec-
tiveness.
We investigate and quantify the relationship between
these 3 factors to investigate the impact of drug pressure
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in driving mutations that encodes CQ and SP resistance in an
area of moderate to high malaria transmission in Papua New
Guinea (PNG). Rather than considering prevalences of these
mutations in patient blood, which is potentially misleading if
there are changes in transmission intensity and multiplicity of
infection (MOI), we present these analyses of the evolution of
resistance in terms of allele and haplotype frequencies [8]. We
then proceed to quantify the impact on failure rates and ther-
apeutic effectiveness.
PATIENTS AND METHODS
Patients and follow-up. The study, part of the Malaria Vac-
cine Epidemiology and Evaluation Project [9–11] in Wosera,
focused on the inhabitants of the immediate catchment area
of the Kunjingini health center in East Sepik Province, PNG.
This health center provided the only source of primary care
for this area [12], and identification (ID) numbers, presumptive
diagnosis, and treatment were recorded for all patients that
presented during the period 1991–2002. ID numbers were then
linked to those in the Wosera demographic surveillance system,
and reattendance at health facilities within any given period of
time was thus recorded.
Patients with fever were treated presumptively for malaria
according to the guidelines of the PNG Department of Health
[13], which for uncomplicated malaria recommended amodia-
quine (AQ) for children !20 kg and CQ for others, until 2000.
From 1997 on, to reduce vivax malaria transmission, 1 dose of
primaquine (PQ) was combined with AQ or CQ. Second-line
treatment was quinine (QN) plus SP. In 2000, the first-line
treatment changed to AQ plus SP or CQ plus SP, depending
on the patient’s weight.
Blood was collected for parasitological and hematological
assessment, and samples were frozen in EDTA-Microtainer
(Becton Dickinson).
The Medical Research and Advisory Committee of the Min-
istry of Health in PNG gave scientific approval and ethical
clearance, and written informed consent was obtained from
patients, parents, or legal guardians before recruitment of each
patient.
Molecular analysis. DNA was extracted by the QIAamp
DNA kit from a random sample of 50 blood samples per year
from cases that presented with 11000 asexual P. falciparum
parasites/mL. Polymorphisms in the pfcrt (C72S, M74I, K76T,
H97Q, T152A, S163R, A220S, Q271E, N326S/D, I356L/T,
R371I), pfmdr1 (N86Y, Y184F, S1034C, N1042D, D1246Y),
pfdhfr (A16V, N51I, C59R, S108N, I164L), and pfdhps (S436A/
F, A437G, K540E, A581G, A613T/S, I640F, H645P) genes were
analyzed by DNA microarray as described elsewhere [14]. MOI
was determined using GeneScan-based msp2 genotyping [15].
Drug use. Drug pressure was measured as the mean num-
ber of treatments per person per year. For 1991–1993, the total
number of treatments dispensed from the clinic was known.
The number of treatments in our study area was then obtained
by multiplying this total by the proportion of the clinic’s catch-
ment falling in our study area (39%, obtained from the total
person-time in the demography database for 1999–2002). Our
experiences during this period suggest that this catchment had
typical levels of patients seeking malaria treatment and that
local demographic characteristics did not alter significantly be-
tween 1991–1993 and 1997–2002. For 1994–1996, no reliable
data on treatments were available. From 1997 onward, treat-
ment data were available from the Institute of Medical Research
(IMR) study nurses who recorded the drugs used during their
visits. They were not present each day, so the total number of
treatments was obtained by dividing the recorded number of
IMR treatments by the proportion of days that the IMR study
team was present. This calculation relies on the assumption
that treatment rates and type were independent of presence of
the IMR nurses, because the nurses’ role was observational.
Allele and haplotype frequencies. Single allele frequencies
of resistance markers were estimated from nonlinear statistical
model by accounting for the effects of varying multiplicity of
infection and by assuming that resistant and sensitive parasite
clones are transmitted independently. The likelihood of a sam-
ple containing no resistant clones is , where p is then(1 p)
frequency for the mutant allele and n is the MOI of the sample.
Similarly, the likelihood of a sample containing no wild-type
allele is , and for a mixture of both, a wild-type and a resistantnp
allele, is . The overall likelihood for p is thenn n1 p –(1 p)
the product of this likelihood over all samples, using values of
n obtained from msp2 genotyping results [16]. We used a simple
1-dimensional search routine to maximize this likelihood and
obtain estimates of p [17]. This maximum likelihood (ML)
analysis is a standard-population genetic approach for samples
whose genetic composition is ambiguous (eg, ambiguity arises
if a sample has MOIp 4 and contains both mutant and wild-
type alleles because it is unclear whether the sample contains
1, 2, or 3 mutant clones). ML emphasizes the probability of
observing the entire data set rather than attempting to un-
ambiguously identify the genetic composition of each sample.
Consequently, it can include all samples, and we were not forced
to discard genetically ambiguous samples when MOI2. Poly-
merase chain reaction (PCR) bias and parasite sequestration
means that minor clones may be missed in some samples and
MOI may be underestimated. However, we are not directly
counting the number of clones of each genotype, so this effect
is not important. We avoid subsequent problems, such as the
most appropriate denominator to use; provided that the prob-
ability of detecting clones is unaffected by the genotype being
analyzed, then the methodology is robust. The frequencies of
distinct haplotypes for pfdhfr and pfdhps were estimated by ML
using the MalHaploFreq program [8]; the ML approach is de-
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Figure 1. Per capita treatment showing use of various drug com-
binations, from 1991 through 2002 (but excluding 1994–1996 due
to lack of data). AQ, amodiaquine, CQ, chloroquine; SP, sulfadoxine-
pyrimethamine.
Figure 2. Changes in mutant allele frequency from 1991 through 2002 as a result of use of sulfadoxine-pyrimethamine in combination with chloroquine
or amodiaquinea.
scribed in more detail in that publication and in the accom-
panying users’ manual.
Selection coefficients were calculated for each allele and hap-
lotype by plotting against time, where R and S are theln (R/S)
frequency of resistant and sensitive alleles or haplotypes, re-
spectively [18]. Time was converted to parasite generations that
assumed 6 P. falciparum generations per year. The selection
coefficient for each single-nucleotide polymorphism (SNP) or
haplotype was the slope obtained by regression analysis for the
12-year period. Annual selection coefficients were also calcu-
lated for correlation with contemporaneous drug usage.
Treatment effectiveness. Treatment failure rates were cal-
culated by year as the proportion of patients with confirmed
malaria administered an antimalarial treatment course who re-
presented with a subsequent episode of confirmed malaria
within 8–28 or 29–42 days of start of treatment [19]. Treatment
courses were provided at health facilities, and subsequent pa-
tient compliance was not noted. Hence, our failure rates reflect
drug effectiveness. It is important not to confuse effectiveness
with drug efficacy measures that arise from clinical trials. The
latter provide drugs in idealized conditions (typically giving
exact doses based on weight and observing compliance) to
confirm that the drug will work in principle, rather than in
practice. Our use of drug failure to measure effectiveness is
more appropriate for 2 main reasons. First, it reflects the real-
life conditions under which people use (and misuse) the drugs.
Second, the impact of mutations depends on their environ-
ment: in principle, they might not compromise drug efficacy
(mutant parasites are always killed by correct treatment) but
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Figure 3. Changes in haplotype frequency from 1991 through 2004.
may reduce effectiveness (mutant parasites may survive the
suboptimal treatments that inevitably occur in practice). Failure
rates were not PCR-corrected, so they include both recrudes-
cent infections that survived treatment and reinfections. Both
are important for effectiveness; mutations to resistance increase
the probability of surviving treatment and also allow parasites
to tolerate high drug levels, thus enabling them to establish
new infections in people more rapidly after treatment [20].
Thus, the absence of PCR correction is not problematic for the
study.
RESULTS
Drug use. A total of 7612 AQ, 5179 CQ, 337 QN, 2571 SP,
and 4430 PQ treatments were delivered at the Kunjingini Health
Center to patients from the core villages from 1991 through
2002, corresponding to an average of 0.81 treatment courses
per person-year. From 1991 through 1993, only AQ, CQ, and
QN were prescribed. Per capita treatment decreased for AQ
and CQ between 1991 and 1999 (with the proviso that data
for 1994–1996 were not available), remaining relatively stable
thereafter (Figure 1), but was always higher for AQ than for
CQ. QN use was low during the entire 12-year period. PQ use
commenced in 1997 with 0.58 treatments per person, increased
to 0.95 in 2000, and then decreased to 0 in 2002 (Figure 1).
SP use started in 1997, with 0.01 treatments per person and
remained low until 1999. SP was then combined with CQ or
AQ as recommended first-line drug, increasing rapidly to 0.86
and 0.74 treatments per person-year in 2001 and 2002, re-
spectively (Figure 2). Slides collected by the IMR team during
their visits showed that 56% of the (presumptively) treated
patients did not have P. falciparum (data not shown), with this
percentage stable over time.
Genetic analyses. MOI showed no significant trend over
time, averaging P. falciparum clones per sample, with1.4 0.15
the lowest MOI in 1991 (1.21) and the highest in 2000 (1.78).
Thus, 98% of samples could be genotyped (588 samples), with
polymorphisms found in pfcrt codons C72S, K76T, H97Q,
A220S, N326D, I356L, and I356T, pfmdr1 codons N86Y, Y184F,
and N1042D, pfdhfr codons C59R and S108N, and pfdhps co-
don A437G. The changes in SNP and haplotype frequencies
are shown in Figures 2 and 3, respectively.
Most mutant allele frequencies increased over the 12-year
period, except pfmdr1 Y184F and N1042D, pfcrt I356T and
H97Q, and pfdhps A437G, which were at low frequencies and
showed no discernible trend. Mutant gene frequencies in pfcrt,
already frequent (10.4) in 1991 (Figure 2), increased over the
12-year period (for pfcrt I356L, C72S, and K76T multiplying
by 1.67, 1.63, and 1.34, respectively). The pfmdr1 N86Y fre-
quency was multiplied by 1.18 (Figure 3). The mutant allele
frequencies of pfdhfr C59R and S108N decreased between 1991
and 1995, from 0.47 to 0.24 for S108N and 0.26 to 0.07 for
C59R. From 1995 onward, the frequencies of these alleles mul-
tiplied by 3 and 6.4, respectively.
Among haplotypes, the frequency of pfdhfr is the most in-
teresting. The wild-type frequency did not vary significantly
between 1991 and 1998, but it dramatically decreased thereafter.
The pfdhfr108 single-mutant haplotype did not change much
in frequency over the entire period. There was no clear trend
for pfdhfr double-mutant haplotype 59R/108N between 1991
and 1997, but after 1998 it increased to a frequency that was
2.5 times higher in 2001 than in 1998 (Figure 3).
The selection coefficients for all the mutations are listed in
Table 1. There was significant selection for the pfcrt SNPs C72S
and I356L ( ) and the pfdhfr SNPs C59R (and S108NP .05
Table 1. Analysis of the Spread and Consequences of Single-Nucleotide Polymorphism (SNPs) and Haplotypes in pfcrt, pfmdr1,
and pfdhfr
SNP or haplotype
Selection coefficient,
% (95% CI)
Correlation between selection
coefficient and drug usage
Correlation
between SNP/haplotype
frequency and
drug failure rates
CQ AQ QN PQ SP ETF LTF
Gene pfcrt. (haplotypes defined
at codons 76, 220, and 356)
SNP C72S 2.60a (1.47 r 3.73) 0.05 0.62 0.68a 0.45 N/A 0.33 0.05
SNP K76T 4.08 (4.90 r 13.05) 0.56 0.43 0.55 0.36 N/A 0.65b 0.01
SNP H97Q 6.13 (2.54 r 14.80) 0.27 0.41 0.42 0.27 N/A 0.63c 0.77a
SNP I356L 2.53a (1.31 r 3.75) 0.04 0.50 0.61 0.45 N/A 0.21 0.07
SNP I356T 4.94 (19.3 r 09.4) 0.003 0.45 0.37 0.41 N/A 0.23 0.14
SNP A220S 2.15 (0.82 r 5.12) 0.35 0.20 0.11 0.07 N/A 0.38 0.13
SNP N326D 1.70 (0.73 r 4.13) 0.47 0.01 0.12 0.18 N/A 0.50 0.02
Haplotype 000 0.025a (0.04 r 0.01) 0.02 0.48 0.60 0.54 N/A 0.21 0.24
Haplotype 001 0.01 (0.11 r 0.13) 0.23 0.04 0.13 0.11 N/A 0.15 0.15
Haplotype 010 0.03 (0.10 r 0.04) 0.21 0.18 0.29 0.37 N/A 0.18 0.02
Haplotype 011 0.03 (0.11 r 0.17) 0.45 0.18 0.13 0.24 N/A 0.27 0.05
Haplotype 100 0.01 (0.13 r 0.11) 0.6 0.27 0.27 0.43 N/A 0.28 0.18
Haplotype 101 0.04 (0.13 r 0.05) 0.05 0.11 0.11 0.55 N/A 0.62c 0.4
Haplotype 110 0.10a (0.19 r 0.005) 0.65b 0.88d 0.82d 0.56 N/A 0.37 0.13
Haplotype 111 0.02 (0.01 r 0.05) 0.26 0.24 0.10 0.11 N/A 0.27 0.02
Gene fmdr1. (haplotypes defined
at codons 86, 184, and
1042)
SNP N86Y 1.03 (0.04 r 2.10) 0.06 0.37 0.58 0.53 N/A 0.49 0.19
SNP Y184F 1.27 (3.73 r 1.20) 0.60 0.55 0.47 0.11 N/A 0.82 d 0.04
SNP N1042D 3.27 (8.76 r 15.31 0.16 0.36 0.17 0.03 N/A 0.17 0.63c
Haplotype 000 0.02a (0.03 r 0.002) 0.003 0.45 0.54 0.69a N/A 0.16 0.04
Haplotype 100 0.01 (0.002 r 0.02) 0.09 0.43 0.51 0.75a N/A 0.24 0.04
Haplotype 101 0.12a (0.01 r 0.24) 0.37 0.64b 0.62 0.26 N/A 0.78a 0.51
Gene pfdhfr (haplotypes defined
at codons 59 and 108)
SNP C59R 2.25a (0.09 r 4.41) N/A N/A N/A N/A 0.83d 0.26 0.35
SNP S108N 1.95a (0.34 r 3.57) N/A N/A N/A N/A 0.92e 0.97 0.92
Haplotype 00 1.76a (3.27 r 0.23) N/A N/A N/A N/A 0.90e 0.97 0.63
Haplotype 01 0.11 (2.45 r 2.69) N/A N/A N/A N/A 0.02 0.25 0.80
Haplotype 11 2.15a (0.03 r 4.27) N/A N/A N/A N/A 0.79d 0.23 0.38
NOTE. Only the main haplotypes and their constituent SNPs are included, identified in the table using “0” to indicate a wild type and “1” to indicate
a mutant. Hence, pfcrt haplotype 001 is wild type at positions 76 and 220 and mutant at position 356; pfmdr1 haplotype 011 is wild type at position
86 and mutant at positions 184 and 1042; and so on. The Table provides 3 key factors describing the spread of resistance: (1) selection coefficients for
CQ and SP resistance-related molecular markers over the whole study period assuming 6 generations of Plasmodium falciparum per year. (2) The
correlation between these selection coefficients (a measure of how rapidly the mutations are spreading or disappearing) and level of individual drug
use. This was done on an annual basis (ie, each year constitutes 1 data point), excluding years 1994–1996 in which there was no quantification of drug
usage. (3) The correlation between the allele/haplotype frequency and early and late treatment failure rates analyzed on an annual basis. In the case of
treatment failures and pfcrt and pfmdr, we only include 1991–1999 (because failure rates are not directly comparable in the periods before and after
the introduction of SP as their partner drug). Similarly, SP was only deployed for 3 years, 2000–2002, so correlation was only over 3 time points. AQ,
amodiaquine; CI, confidence interval; CQ, chloroquine; ETF, early treatment failure (between days 8 and 28); LTF, late treatment failure (between days
29 and 42); N/A, not applicable; QN, quinine; PQ, primaquine; SP, sulfadoxine-pyrimethamine.
a .P .05
b .Pp .06
c .Pp .07
d .P .01
e .P .001
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Figure 4. Treatment failure rates in relation to changes in treatment
policy. AQ, amodiaqine; CQ, chloroquine; SP, sulfadoxine-pyrimethamine.
( ). Among the pfcrt haplotypes, there was low but sig-P .05
nificant selection against the triple wild-type haplotype and
against the double-mutant 76/220 haplotype. In pfmdr, there
was significant selection against the triple wild-type haplotype
and positive selection for the double-mutant 86/1042 haplo-
type. There was significant selection for the pfdhfr double-mu-
tant haplotype and significant selection against the pfdhfr 59/
108 wild-type haplotype. In particular, the selection coefficient
for the pfdhfr 59/108 double mutant after 1999 (ie, after the
change to SP plus AQ or SP plus CQ as a first drug in 2000)
was 4.87% (data not shown), but it was not significant
(14.34% to 24.07%).
The correlations between selection coefficients and drug use
patterns were nonsignificant for nearly all the pfcrt and pfmdr1
mutations and QN, AQ, and CQ use, except for pfcrt C72S and
QN use, and pfcrt 76/220 haplotype and AQ and QN use (Table
1). In contrast, the correlations between selection coefficients
of pfdhfr SNPs and haplotypes and SP use were significantly
positive.
Treatment effectiveness. Overall, 148 (2.2%) of 6678
treated patients were reinfected during the 8–28-day period and
an additional 122 (1.8%) patients were reinfected during the
29–42-day follow-up period. The treatment failure rate for the
28-day follow-up period did not change significantly between
1991 and 1995, but it gradually increased from 1996 until 1999;
treatment failures were 3.8 times more common in 1999 than
in 1996 (Figure 4). Patient follow-up was not recorded in 1995.
After 1999, the treatment failure rate decreased dramatically,
resulting in a treatment failure rate that was 3.5 lower in 2002
than it was in 1999 (Figure 1). There was no significant overall
trend for treatment failure rates over the 29–42-day follow-up
period. Nevertheless, treatment failure during that period was
3.8 times more likely in 2002 than in 1991 (Figure 4).
DISCUSSION
Over the 12-year study period, annual drug use was ∼1 treat-
ment per person, consistent with the area being of moderate
to high intensity of transmission, with little drug access outside
the formal health sector [10]. There was a gradual decline in
deployment of AQ and CQ, whereas use of SP was high, fol-
lowing its introduction in 2000. Despite little use of SP before
2000, pfdhfr108 and pfdhfr59 mutations were already present
in 1991, and there was significant selection for these mutations
even without evident SP use (Table 1 and Figures 2 and 3).
Several explanations are possible: first, trimethoprim-sulfa-
methoxazole, an antifolate used mainly for its antibacterial ef-
fect, could select for pfdhfr mutations [21]. Second, SP was not
systematically recorded when it was given with QN as a second-
line treatment. Third, resistant parasites could immigrate from
neighboring areas, where SP resistance was higher. Fourth, ef-
fects of antifolate pressure exerted by mass drug administration
of pyrimethamine in the 1960s and 1970s were persistent [22].
Any of these explanations would be compatible with the model
that the acquisition of mutations enabling parasites to become
tolerant takes much longer than subsequent acquisition of sol-
id resistance [23]. The haplotypes of genes, rather than poly-
morphisms at individual codons, are the basic unit of drug
selection. Evolution of resistance may proceed through a series
of haplotype turnovers, some haplotypes initially spreading be-
fore being replaced in turn by more-resistant haplotypes [23].
Interestingly, our analyses suggest that resistance is in very dif-
ferent stages of development (Figure 3) in the 4 genes; pfdhps
is represented essentially by only wild-type haplotypes. Mutants
occur only on a single codon 86 in pfmdr1, although there was
a late appearance of a double pfmdr86/1042 haplotype. In pfcrt
the wild-type haplotype was almost eliminated and replaced by
the 76/356 and 76/220/356 mutant haplotypes, with the triple
mutant eventually largely displacing the double mutant.
In pfdhfr, the wild-type haplotype shows a steady decline
with the 108 single-mutant haplotype, initially being slowly
displaced by the 59/108 double-mutant haplotype but increas-
ing rapidly after the introduction of SP as a first-line drug in
1999. The estimated selection coefficient was 4.9% after this
introduction, and although the sample size was tiny (3-year
points), resulting in a large confidence interval (14% to 24%),
it is interesting that this estimate is almost identical to that of
5% reported by Anderson and Roper [18], despite their work
being performed in a low-transmission area and examining a
more highly resistant pfdhfr triple mutant haplotype, which
would have been displacing the double.
Note that these selection coefficients are overall values, which
reflect both the advantage of the mutations in the presence of
a drug and their possible disadvantage in untreated individuals
[24–28]. The selective disadvantage of pfcrtK76T in the absence
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of drug treatment was previously estimated at 5% [27] in
Malawi, so making an illustrative assumption that the advan-
tage in the presence of the drug is +25% and that 30% of infec-
tions are treated would give an overall selection coefficient
of . Obviously, as drug use(0.3 0.25) + (0.70.05)p 0.04
increases or decreases, this overall selection coefficient will
change; hence, the importance of examining the correlation
between the 2 parameters is clear (Table 1). In principle, it
should be possible to disentangle the 2 effects by regressing the
selection coefficient against drug use and finding where the
regression cuts the Y axis (when drug use p 0), which would
give the selective disadvantage in the absence of the drug, but
in practice the relationship was so weak as to preclude this
calculation.
The sign and magnitude of these selection coefficients, s, is
a key parameter in much of population genetic theory. For
example, the magnitude of s affects the following:
1. The rate at which mutations and haplotypes migrate
across geographic regions. Classically, the rate is , wherej (2s)
j is the standard deviation of parasite dispersal via host move-
ment ([23]; but see the brief discussion in the Appendix of
[29]).
2. The chance of new mutations surviving the first few
generations after their first appearance or introduction (see box
2 of [30]).
3. The mutation/selection balance and hence the frequency
of the mutation that would be present before drugs are deployed
[31].
4. The size of the selective sweep in the genome surround-
ing a mutation being selected for resistance [32].
The estimates for s given in Table 1 can therefore be used to
calibrate and inform broader discussions of the population ge-
netics of emergence and spread of resistance. They can also be
used to validate models of the spread of resistant mutations,
which should predict selection coefficients similar to those ob-
served in the field. Although the estimates of s are imprecise,
the results are remarkably consistent (Table 1). Despite the
central role of the selection coefficient in understanding the
dynamics of resistance, in addition to the value of 5% estimated
for pfdhfr by Anderson and Roper [18], the only other estimate
of selection coefficients acting on P. falciparum drug-resistant
mutations/haplotypes appears to be that of Nair et al [33]. They
used the decline in clinical effectiveness of SP rather than direct
frequency estimation to assess the selection coefficient acting
on dhfr resistance as 11%. The results summarized in Table 1
are therefore a substantive advance.
The increasing treatment failure rate between 1996 and 1999
can be ascribed to the increasing parasite resistance to standard
treatment with CQ and AQ [34, 35], consistent with increasing
frequencies of the CQ resistance–associated mutant alleles in
pfcrt and pfmdr1. Although AQ in combination with SP is
efficacious in some areas where both drugs have previously been
used in monotherapy [36, 37], this drug combination is already
failing in PNG [38–40]. Our data have shown that resistant
pfdhfr allele frequencies already began to increase in 1998 before
the large-scale use of SP. The addition of SP to AQ or CQ in
2000 improved the effectiveness of the standard treatment but
did not prevent the increase in 4-aminoquinolines resistance
in this situation where resistant alleles were already frequent.
Treatment failure rates by day 28 with combination therapy
reached 16% in Wosera in 2003 [38]. Later molecular data have
also confirmed that resistance to SP, as measured by pfdhfr
S108N and C59R frequencies, continued to increase steadily
from 1999 onward [39, 40].
Few previous studies have assessed the relationships between
therapeutic effectiveness and molecular resistance markers over
extended periods [41–43]. The only other study, in Senegal
[19], to correlate these with drug pressure found results similar
to ours. The frequencies of both resistance markers and clinical
failure to both SP and CQ increased rapidly despite restriction
of antimalarial treatments to parasitologically confirmed cases
[19].
We conclude by considering how closely the 3 parts of the
process leading to resistance interrelate. There were strong cor-
relations between SP use and pfdhfr selection coefficients but
little correlation between drug use and selection coefficients in
either pfcrt or pfmdr1, probably because mutations known to
be associated with resistance (pfcrtK76T and pfmdrN86Y) were
already present at high frequencies. There also appears to be a
closer relationship between mutations in pfdhfr and SP resis-
tance than there is between pfmdr1/pfcrt mutations and CQ/
AQ failures. The weak correlations between individual muta-
tion/haplotype frequency and CQ/AQ failure rates very likely
reflect other phenomena, such as external factors that include
pharmacogenetics, compliance, and host immunity.
The genetic component was the most illuminating. The ge-
netic basis of resistance is known for several drugs, and there
is increasing interest in using molecular monitoring as a tool
to assess resistance [44–46] and to influence treatment poli-
cy change [47, 48]. We demonstrated the ability to use high-
throughput screening to simultaneously genotype P. falciparum
at numerous loci and could estimate frequencies of individual
alleles and haplotypes, which are the basic units of drug selec-
tion, and selection coefficients (consistently in the range of 1%–
4%). These analyses provide a valuable resource to inform ge-
netic modeling of drug resistance and, more generally, con-
tribute to effective and appropriate use of genetic surveillance
to support and guide antimalarial drug deployment policy.
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